×
About 2,070 results

ALLMedicine™ Hypopituitarism Center

Research & Reviews  757 results

17-Ketosteroids
https://emedicine.medscape.com/article/2089246-print

May 13th, 2022 - The reference range of urinary 17-ketosteroids is as follows[1] : Males: 10-20 mg (34-69 µmol)/24 h Females: 5-15 mg (17-52 µmol)/24 h Increases in levels of 24-hour urinary 17-ketosteroids are associated with the following: Adrenal tumors Cushing...

Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040214
BMC Endocrine Disorders; Yamada H, Washino S et. al.

Apr 27th, 2022 - This study aimed to evaluate whether hypereosinophilia is a clinical biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma treated with nivolumab plus ipilimumab. This was a retrospective cohort stu...

Panhypopituitarism
https://emedicine.medscape.com/article/923789-print

Apr 21st, 2022 - Practice Essentials The pituitary gland is called the master endocrine gland of the body because it controls the function of other endocrine organs. The anterior pituitary produces the hormones thyrotropin (thyroid-stimulating hormone [TSH]), cort...

The sellar region as presenting theater for hematologic malignancies-A 17-year single-c...
https://doi.org/10.1507/endocrj.EJ21-0790
Endocrine Journal; Pekic S, Stojanovic M et. al.

Apr 12th, 2022 - Hematological neoplastic mass lesions of the sellar region are rare. We identified five cases of hematological malignancy with first presentation in the sellar region from our departmental database of 1,405 patients (0.36%) with sellar lesions dia...

see more →

Guidelines  5 results

Management of immune-related adverse events in endocrine organs induced by immune check...
https://doi.org/10.1507/endocrj.EJ19-0163
Endocrine Journal; Arima H, Iwama S et. al.

Jun 28th, 2019 - Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve,...

Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practi...
https://doi.org/10.1210/jc.2016-2118
The Journal of Clinical Endocrinology and Metabolism; Fleseriu M, Hashim IA et. al.

Nov 5th, 2016 - To formulate clinical practice guidelines for hormonal replacement in hypopituitarism in adults. The participants include an Endocrine Society-appointed Task Force of six experts, a methodologist, and a medical writer. The American Association for...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pri...
https://doi.org/10.1227/NEU.0000000000001389
Neurosurgery Lucas JW, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present clinically with vision loss and hypopituitarism. To characterize the existing literature as it pertains to the initial management of NFPAs. A sys...

Pituitary incidentaloma: an endocrine society clinical practice guideline.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393422
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.

Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  17 results

Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)
https://clinicaltrials.gov/ct2/show/NCT05319301

Apr 8th, 2022 - Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated wi...

Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes
https://clinicaltrials.gov/ct2/show/NCT05206149

Jan 25th, 2022 - The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function, representing a stimulus f...

Observing the Changes of Endocrine and Metabolism in Patients With Thalassemia Major
https://clinicaltrials.gov/ct2/show/NCT03951818

Feb 18th, 2021 - Patient with thalassemia major have many endocrine diseases, such as hypopituitarism, hypothyroidism, hypoparathyroidis, osteoporosis, and etc.. These problems may be due to anemia itself or related to iron deposition. This study aimed to investig...

Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
https://clinicaltrials.gov/ct2/show/NCT00507104

Dec 14th, 2020 - Recent data have demonstrated that hypopituitarism seems to be a frequent finding after traumatic brain injury (TBI) and/or subarachnoid hemorrhage (SAH). However, most of these studies referred to retrospective evaluations. There are only few pro...

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
https://clinicaltrials.gov/ct2/show/NCT00182091

Sep 2nd, 2020 - The aim of the study is to evaluate the effects of physiologic growth hormone (GH) replacement on cardiovascular risk markers, cardiac autonomic function, arterial distensibility, body composition, and quality of life in men and women with GH defi...

see more →

News  43 results

Multidisciplinary Care for Malignant Melanoma
https://www.onclive.com/view/multidisciplinary-care-for-malignant-melanoma

Apr 2nd, 2021 - For High-Definition, Click The treatment of patients with metastatic melanoma requires a team approach. The complexities of this disease warrants impute from several specialists to properly deliver care, the panelists agree. Along these lines, h...

I/O Second-Line Treatment
https://www.onclive.com/view/i-o-second-line-treatment

Apr 2nd, 2021 - Peter Galle, MD: What do we have as evidence? The only I/O agent that has been convincing in demonstrating benefit was atezolizumab in combination with bevacizumab in first line. That’s what we have. The monotherapy has not made it into a signific...

FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma
https://www.onclive.com/view/fda-approves-two-new-indications-for-pembrolizumab-in-advanced-melanoma

Dec 4th, 2020 - Roger M. Perlmutter, MD, PhD The FDA has expanded the approval for single-agent pembrolizumab (Keytruda) to include the frontline treatment of patients with advanced melanoma regardless of BRAF status, based on a substantial improvement in progre...

Fast Five Quiz: Test Your Knowledge of Acromegaly
https://reference.medscape.com/viewarticle/875763_6

Sep 16th, 2020 - Answer 5/5 Which of the following is accurate regarding treatment of acromegaly? Your peers chose: Pharmacologic therapy is the first-line treatment for acromegaly 0% Radiation therapy is routinely indicated for most patients with acromegaly 0% Fo...

Guidance for Endocrinologists During COVID-19 Pandemic
https://www.medpagetoday.com/endocrinology/generalendocrinology/85879

Apr 9th, 2020 - In response to the COVID-19 pandemic, endocrinologists should take certain precautions with patients they commonly treat, according to new guidance from editors of The Journal of Clinical Endocrinology & Metabolism. Editor-in-Chief Paul Stewart, M...

see more →

Patient Education  5 results see all →